翰宇药业(300199.SZ)：上半年净利润1.45亿元 同比扭亏

Core Viewpoint - Hanyu Pharmaceutical (300199.SZ) reported significant growth in its financial performance for the first half of 2025, indicating a strong recovery and operational efficiency [1] Financial Performance - The company achieved operating revenue of 549 million yuan, representing a year-on-year increase of 114.86% [1] - Net profit attributable to shareholders of the listed company was 145 million yuan, marking a turnaround from a loss to profit [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 123 million yuan [1] - Basic earnings per share stood at 0.16 yuan [1]